Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miriam Koopman

Showing results (131-140 of 193) with videos related to

Pageof 20
Sort By:
Clinical Colorectal Cancer|December 23, 2022
Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal CancerSanne Ten Hoorn, Linda Mol, Dirkje W Sommeijer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trialsKenta Iguchi, Kentaro Yamazaki, Toshihiro Misumi, et al.
JNCI Cancer Spectrum|April 25, 2025
Associations between early tumor shrinkage/depth of response and survival from the ARCAD databaseHideaki Bando, Yuriko Takeda, Toshihiro Misumi, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
BMC Cancer|July 19, 2012
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patientsLeonie J M Mekenkamp, Jolien Tol, Jeroen R Dijkstra, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 8, 2024
Development of a prediction model for clinically-relevant fatigue: a multi-cancer approachDhirendra Adiprakoso, Dimitris Katsimpokis, Simone Oerlemans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2016
WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based TherapyLinda J W Bosch, Yanxin Luo, Victoria V Lao, et al.
Clinical Pharmacology and Therapeutics|February 11, 2026
Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World DataFrancesco Pignatti, Tarec Christoffer El-Galaly, Martin Kaiser, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 28, 2020
Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)Gabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, et al.
International Journal of Cancer|August 8, 2024
Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancerSimone van de Weerd, Arezo Torang, Inge van den Berg, et al.
Pageof 20

Showing results (131-140 of 193) with videos related to

Sort By:
Pageof 20
Clinical Colorectal Cancer|December 23, 2022
Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal CancerSanne Ten Hoorn, Linda Mol, Dirkje W Sommeijer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trialsKenta Iguchi, Kentaro Yamazaki, Toshihiro Misumi, et al.
JNCI Cancer Spectrum|April 25, 2025
Associations between early tumor shrinkage/depth of response and survival from the ARCAD databaseHideaki Bando, Yuriko Takeda, Toshihiro Misumi, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
BMC Cancer|July 19, 2012
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patientsLeonie J M Mekenkamp, Jolien Tol, Jeroen R Dijkstra, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 8, 2024
Development of a prediction model for clinically-relevant fatigue: a multi-cancer approachDhirendra Adiprakoso, Dimitris Katsimpokis, Simone Oerlemans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2016
WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based TherapyLinda J W Bosch, Yanxin Luo, Victoria V Lao, et al.
Clinical Pharmacology and Therapeutics|February 11, 2026
Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World DataFrancesco Pignatti, Tarec Christoffer El-Galaly, Martin Kaiser, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 28, 2020
Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)Gabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, et al.
International Journal of Cancer|August 8, 2024
Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancerSimone van de Weerd, Arezo Torang, Inge van den Berg, et al.
Pageof 20